Empagliflozin cost ‐effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction

ConclusionsEmpagliflozin was demonstrated to be cost-effective for patients with HFpEF in Japan based on EMPEROR-Preserved trial data.

Source: ESC Heart Failure - November 16, 2023 Category: Cardiology Authors: Hiroyuki Tsutsui, Hiroyuki Sakamaki, Shin ‐ichi Momomura, Yasushi Sakata, Yutaro Kotobuki, Stephan Linden, Koki Idehara, Daisuke Nitta Tags: Original Article Source Type: research